VTVT has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
VTVT has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, vTv Therapeutics's enterprise value is $49.84 Mil. vTv Therapeutics's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $0.00 Mil. Therefore, vTv Therapeutics's EV-to-Revenue for today is .
The historical rank and industry rank for vTv Therapeutics's EV-to-Revenue or its related term are showing as below:
During the past 11 years, the highest EV-to-Revenue of vTv Therapeutics was 7441.77. The lowest was -72.84. And the median was 18.07.
The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.
EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.
As of today (2024-04-18), vTv Therapeutics's stock price is $24.00. vTv Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.00. Therefore, vTv Therapeutics's PS Ratio for today is .
The historical data trend for vTv Therapeutics's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, vTv Therapeutics's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, vTv Therapeutics's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where vTv Therapeutics's EV-to-Revenue falls into.
EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.
vTv Therapeutics's EV-to-Revenue for today is calculated as:
EV-to-Revenue | = | Enterprise Value (Today) | / | Revenue (TTM) |
= | 49.836 | / | 0 | |
= |
vTv Therapeutics's current Enterprise Value is $49.84 Mil.
vTv Therapeutics's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
vTv Therapeutics (NAS:VTVT) EV-to-Revenue Explanation
The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.
vTv Therapeutics's PS Ratiofor today is calculated as:
PS Ratio | = | Share Price (Today) | / | Revenue per Share (TTM) |
= | 24.00 | / | 0 | |
= |
vTv Therapeutics's share price for today is $24.00.
vTv Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of vTv Therapeutics's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Steven L. Tuch | officer: Chief Financial Officer | C/O VTV THERAPEUTICS INC., 3980 PREMIER DRIVE, HIGH POINT NC 27265 |
John A Fry | director | C/O DELAWARE INVESTMENTS, 2005 MARKET ST. 34TH FL., PHILADELPHIA PA 19103 |
Jonathan Isaacsohn | director | C/O VTV THERAPEUTICS INC., 3980 PREMIER DRIVE, HIGH POINT NC 27265 |
Paul J Sekhri | director, officer: President and CEO | C/O VEEVA SYSTEMS INC., 4637 CHABOT DRIVE, SUITE 210, PLEASANTON CA 94588 |
Fahed Al-marzooqi | director | AL KHATEM TOWER, ABU DHABI GLOBAL MARKET, ABU DHABI C0 00000 |
Keith R. Harris | director | C/O MEIRAGTX - US, 430 EAST 29TH STREET, 10TH FLOOR, NEW YORK NY 10016 |
Hersh Kozlov | director | WOLF BLOCK SCHORR & SOLIS, 1940 RTE 70 E, CHERRY HILL NJ 08003 |
Howard L. Weiner | director | 4170 MENDENHALL OAKS PKWY, HIGH POINT NC 27265 |
Chandresh Harjivan | director | C/O VTV THERAPEUTICS INC., 3980 PREMIER DRIVE, HIGH POINT NC 27265 |
Al-nahyan Tahnoon Bin Zayed S. | 10 percent owner | OFFICE 2458, FLOOR 24, AL-SILA TOWER, ABU DHABI C0 00000 |
G42 Investments Ai Holdings Rsc Ltd. | director, 10 percent owner | OFFICE 801, FLOOR 8, AL KHATEM TOWER, ABU DHABI C0 00000 |
Barry K. Brown | officer: Chief Accounting Officer | C/O VTV THERAPEUTICS INC., 3980 PREMIER DRIVE, HIGH POINT NC 27265 |
Rich S. Nelson | director, officer: Acting Chief Executive Officer | C/O VTV THERAPEUTICS INC., 3980 PREMIER DRIVE, HIGH POINT NC 27265 |
Ronald O Perelman | 10 percent owner | 35 EAST 62ND STREET, NEW YORK NY 10021 |
Deepa Prasad | director, officer: President and CEO | C/O VTV THERAPEUTICS INC., 3980 PREMIER DRIVE, SUITE 310, HIGH POINT NC 27265 |
From GuruFocus
By Marketwired • 08-11-2023
By GuruFocusNews GuruFocusNews • 06-24-2022
By PRNewswire • 09-18-2023
By PurpleRose PurpleRose • 07-11-2022
By PRNewswire PRNewswire • 01-09-2023
By PurpleRose PurpleRose • 07-27-2022
By Stock market mentor Stock market mentor • 02-01-2023
By GuruFocusNews GuruFocusNews • 06-21-2022
By Value_Insider Value_Insider • 12-13-2022
By GuruFocusNews GuruFocusNews • 06-21-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.